EA037185B1 - Способ лечения психоза, шизофрении или биполярного расстройства - Google Patents

Способ лечения психоза, шизофрении или биполярного расстройства Download PDF

Info

Publication number
EA037185B1
EA037185B1 EA201792209A EA201792209A EA037185B1 EA 037185 B1 EA037185 B1 EA 037185B1 EA 201792209 A EA201792209 A EA 201792209A EA 201792209 A EA201792209 A EA 201792209A EA 037185 B1 EA037185 B1 EA 037185B1
Authority
EA
Eurasian Patent Office
Prior art keywords
dose
reinitial
pp1m
administration
meq
Prior art date
Application number
EA201792209A
Other languages
English (en)
Russian (ru)
Other versions
EA201792209A1 (ru
Inventor
Шрихари Гопал
Паулин Герарда Мария Равенстейн
Альберто Руссу
Махеш Нараин Самтани
Original Assignee
Янссен Фармацевтика Н.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57072843&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA037185(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Янссен Фармацевтика Н.В. filed Critical Янссен Фармацевтика Н.В.
Publication of EA201792209A1 publication Critical patent/EA201792209A1/ru
Publication of EA037185B1 publication Critical patent/EA037185B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
EA201792209A 2015-04-07 2016-03-30 Способ лечения психоза, шизофрении или биполярного расстройства EA037185B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562144054P 2015-04-07 2015-04-07
US201562162596P 2015-05-15 2015-05-15
PCT/US2016/024841 WO2016164218A1 (en) 2015-04-07 2016-03-30 Dosing regimen for missed doses for long-acting injectable paliperidone esters

Publications (2)

Publication Number Publication Date
EA201792209A1 EA201792209A1 (ru) 2018-02-28
EA037185B1 true EA037185B1 (ru) 2021-02-17

Family

ID=57072843

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201792209A EA037185B1 (ru) 2015-04-07 2016-03-30 Способ лечения психоза, шизофрении или биполярного расстройства

Country Status (27)

Country Link
US (1) US10143693B2 (OSRAM)
EP (3) EP4349323A3 (OSRAM)
JP (3) JP6728221B2 (OSRAM)
KR (3) KR102755145B1 (OSRAM)
AU (4) AU2016244801B2 (OSRAM)
BR (1) BR112017021383A2 (OSRAM)
CA (2) CA3088401A1 (OSRAM)
CY (1) CY1123203T1 (OSRAM)
DK (2) DK3280416T3 (OSRAM)
EA (1) EA037185B1 (OSRAM)
ES (2) ES2802299T3 (OSRAM)
FI (1) FI3744326T3 (OSRAM)
HR (2) HRP20240022T1 (OSRAM)
HU (2) HUE049485T2 (OSRAM)
IL (3) IL254669B2 (OSRAM)
LT (2) LT3280416T (OSRAM)
MA (1) MA41917B1 (OSRAM)
MD (2) MD3280416T2 (OSRAM)
NZ (1) NZ735952A (OSRAM)
PL (2) PL3280416T3 (OSRAM)
PT (2) PT3744326T (OSRAM)
RS (2) RS65024B1 (OSRAM)
SI (2) SI3280416T1 (OSRAM)
SM (2) SMT202000351T1 (OSRAM)
TW (1) TWI694825B (OSRAM)
UA (1) UA118732C2 (OSRAM)
WO (1) WO2016164218A1 (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2802299T3 (es) 2015-04-07 2021-01-18 Janssen Pharmaceuticals Inc Régimen de dosificación para dosis olvidadas para ésteres de paliperidona inyectables de acción prolongada
CA3077224A1 (en) 2017-10-27 2019-05-02 Shandong Luye Pharmaceutical Co., Ltd. Dosage regimen of paliperidone palmitate extended-release injectable suspension
EP4385564A3 (en) * 2020-11-30 2024-10-09 JANSSEN Pharmaceutica NV Dosing regimens associated with extended release paliperidone injectable formulations
JP2023551007A (ja) * 2020-11-30 2023-12-06 ヤンセン ファーマシューティカ エヌ．ベー． パルミチン酸パリペリドン製剤の再懸濁を確実にする方法
EP4025189B1 (en) 2020-11-30 2024-06-05 Janssen Pharmaceutica NV Dosing regimens associated with extended release paliperidone injectable formulations
DK4025188T3 (da) * 2020-11-30 2024-03-04 Janssen Pharmaceutica Nv Doseringsregimer associeret med injicerbare paliperidonformuleringer med forlænget frigivelse
CA3229731A1 (en) 2021-08-20 2023-02-23 Janssen Pharmaceutica Nv Dosing regimens associated with extended release paliperidone injectable formulations
IL311134A (en) * 2021-08-30 2024-04-01 Janssen Pharmaceutica Nv Dosing regimens associated with delayed-release paliperidone injection formulations
KR102869809B1 (ko) 2023-11-21 2025-10-13 주식회사 엘지에너지솔루션 양극 및 이를 포함하는 전고체 전지

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090163519A1 (en) * 2007-12-19 2009-06-25 An Vermeulen Dosing regimen associated with long acting injectable paliperidone esters
US20110105536A1 (en) * 2009-10-30 2011-05-05 Lewyn-Briscoe Peter H Dosing regimen associated with long-acting injectable paliperidone esters
US20120277253A1 (en) * 2009-10-06 2012-11-01 Sprogoee Kennett Subcutaneous paliperidone composition
EP2529757A1 (en) * 2011-05-31 2012-12-05 Laboratorios Farmaceuticos Rovi, S.A. Paliperidone implant formulation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5158952A (en) 1988-11-07 1992-10-27 Janssen Pharmaceutica N.V. 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use
US5254556A (en) 1988-11-07 1993-10-19 Janssen Pharmaceutica N.V. 3-piperidinyl-1,2-benzisoxazoles
TW487572B (en) 1996-05-20 2002-05-21 Janssen Pharmaceutica Nv Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
EP1879890A1 (en) 2005-04-25 2008-01-23 Janssen Pharmaceutica N.V. Preparation of aseptic 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4h-pyridio[1,2-a]pyrimidin-4-one palmitate ester
ES2802299T3 (es) 2015-04-07 2021-01-18 Janssen Pharmaceuticals Inc Régimen de dosificación para dosis olvidadas para ésteres de paliperidona inyectables de acción prolongada

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090163519A1 (en) * 2007-12-19 2009-06-25 An Vermeulen Dosing regimen associated with long acting injectable paliperidone esters
US20120277253A1 (en) * 2009-10-06 2012-11-01 Sprogoee Kennett Subcutaneous paliperidone composition
US20110105536A1 (en) * 2009-10-30 2011-05-05 Lewyn-Briscoe Peter H Dosing regimen associated with long-acting injectable paliperidone esters
EP2529757A1 (en) * 2011-05-31 2012-12-05 Laboratorios Farmaceuticos Rovi, S.A. Paliperidone implant formulation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Osborne et al. "Health-related quality of life advantage of longacting injectable antipsychotic treatment for schizophrenia a time trade-off study", Health and Quality of Life Outcomes, Vol. 10, Number 1, Issue 35 (02 April 2012), pages 1-9, page 2, col. 1, para 2, page 2, col. 1, para 3, page 8, col. 2, para 1 *

Also Published As

Publication number Publication date
SI3280416T1 (sl) 2020-07-31
DK3280416T3 (da) 2020-05-11
US20170281629A1 (en) 2017-10-05
ES2802299T3 (es) 2021-01-18
PT3280416T (pt) 2020-06-30
LT3280416T (lt) 2020-06-25
TWI694825B (zh) 2020-06-01
AU2016244801A1 (en) 2017-10-05
PL3744326T3 (pl) 2024-03-25
AU2024227790A1 (en) 2024-11-21
AU2020239611B2 (en) 2022-07-21
LT3744326T (lt) 2023-12-27
IL309340A (en) 2024-02-01
SMT202000351T1 (it) 2020-09-10
JP2018510894A (ja) 2018-04-19
RS65024B1 (sr) 2024-01-31
MD3280416T2 (ro) 2020-10-31
HUE049485T2 (hu) 2020-09-28
JP7422277B2 (ja) 2024-01-26
SMT202300478T1 (it) 2024-01-10
US10143693B2 (en) 2018-12-04
KR102606678B1 (ko) 2023-11-24
AU2016244801B2 (en) 2020-06-25
UA118732C2 (uk) 2019-02-25
NZ758246A (en) 2024-05-31
EP4349323A2 (en) 2024-04-10
EP3280416A4 (en) 2019-01-23
AU2022221405B2 (en) 2024-08-01
HK1249047A1 (en) 2018-10-26
EP4349323A3 (en) 2024-06-12
CA3088401A1 (en) 2016-10-07
CA2925908C (en) 2020-09-01
MD3744326T2 (ro) 2024-05-31
EP3280416B1 (en) 2020-04-22
SI3744326T1 (sl) 2024-02-29
AU2020239611A1 (en) 2020-10-15
KR20170134583A (ko) 2017-12-06
JP2021130680A (ja) 2021-09-09
PL3280416T3 (pl) 2020-12-14
AU2022221405A1 (en) 2022-09-15
KR20230162162A (ko) 2023-11-28
WO2016164218A1 (en) 2016-10-13
ES2967585T3 (es) 2024-05-03
IL254669B1 (en) 2024-01-01
CY1123203T1 (el) 2021-10-29
IL254669B2 (en) 2024-05-01
FI3744326T3 (fi) 2024-02-02
MA41917B1 (fr) 2020-07-29
EP3280416A1 (en) 2018-02-14
NZ735952A (en) 2022-02-25
KR20250013293A (ko) 2025-01-31
JP6728221B2 (ja) 2020-07-22
JP2020090498A (ja) 2020-06-11
EP3744326B1 (en) 2023-12-06
PT3744326T (pt) 2024-01-15
JP7228503B2 (ja) 2023-02-24
EP3744326A1 (en) 2020-12-02
IL324059A (en) 2025-12-01
BR112017021383A2 (pt) 2018-07-03
IL254669A0 (en) 2017-11-30
HRP20201027T1 (hr) 2020-12-11
DK3744326T3 (da) 2024-02-05
EA201792209A1 (ru) 2018-02-28
RS60510B1 (sr) 2020-08-31
CA2925908A1 (en) 2016-10-07
KR102755145B1 (ko) 2025-01-14
HRP20240022T1 (hr) 2024-03-29
HUE065435T2 (hu) 2024-05-28
TW201642863A (zh) 2016-12-16

Similar Documents

Publication Publication Date Title
EA037185B1 (ru) Способ лечения психоза, шизофрении или биполярного расстройства
TWI897289B (zh) 與延釋帕利哌酮可注射配製物相關之投藥方案(二)
TWI877363B (zh) 與延釋帕利哌酮可注射配製物相關之投藥方案（三）
KR20240052810A (ko) 서방형 팔리페리돈 주사용 제형과 관련된 투약 요법
JP2023551009A (ja) 持続放出パリペリドン注射可能製剤に関連する投与レジメン
KR20240049580A (ko) 서방형 팔리페리돈 주사용 제형과 관련된 투약 요법
HK40044495B (en) Dosing regimen for missed doses for long-acting injectable paliperidone esters
HK40044495A (en) Dosing regimen for missed doses for long-acting injectable paliperidone esters
EA050359B1 (ru) Схемы применения инъекционных составов с пролонгированным высвобождением палиперидона
HK1249047B (en) Dosing regimen for missed doses for long-acting injectable paliperidone esters